Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, Exact Sciences Corp’s stock clocked out at $67.5, up 1.38% from its previous closing price of $66.58. In other words, the price has increased by $1.38 from its previous closing price. On the day, 2.55 million shares were traded. EXAS stock price reached its highest trading level at $68.12 during the session, while it also had its lowest trading level at $66.25.
Ratios:
To gain a deeper understanding of EXAS’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 12.75 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 51.76. For the most recent quarter (mrq), Quick Ratio is recorded 2.44 and its Current Ratio is at 2.72. In the meantime, Its Debt-to-Equity ratio is 1.01 whereas as Long-Term Debt/Eq ratio is at 1.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Mizuho on April 10, 2025, initiated with a Outperform rating and assigned the stock a target price of $60.
On March 13, 2025, RBC Capital Mkts started tracking the stock assigning a Sector Perform rating and target price of $52.
On January 23, 2025, Barclays started tracking the stock assigning a Overweight rating and target price of $70.Barclays initiated its Overweight rating on January 23, 2025, with a $70 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 04 ’25 when Herriott James sold 1,500 shares for $70.08 per share. The transaction valued at 105,120 led to the insider holds 12,585 shares of the business.
Baranick Brian sold 2,858 shares of EXAS for $200,289 on Nov 04 ’25. The EVP, GM, Precision Oncology now owns 22,368 shares after completing the transaction at $70.08 per share. On Nov 04 ’25, another insider, Baranick Brian, who serves as the Officer of the company, bought 2,858 shares for $70.08 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, EXAS now has a Market Capitalization of 12789312512 and an Enterprise Value of 14321291264. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.15 while its Price-to-Book (P/B) ratio in mrq is 5.11. Its current Enterprise Value per Revenue stands at 4.647 whereas that against EBITDA is 132.63.
Stock Price History:
The Beta on a monthly basis for EXAS is 1.47, which has changed by 0.31243837 over the last 52 weeks, in comparison to a change of 0.14151978 over the same period for the S&P500. Over the past 52 weeks, EXAS has reached a high of $72.81, while it has fallen to a 52-week low of $38.81. The 50-Day Moving Average of the stock is 14.67%, while the 200-Day Moving Average is calculated to be 30.13%.
Shares Statistics:
It appears that EXAS traded 2.76M shares on average per day over the past three months and 3593250 shares per day over the past ten days. A total of 189.45M shares are outstanding, with a floating share count of 186.89M. Insiders hold about 1.36% of the company’s shares, while institutions hold 96.67% stake in the company. Shares short for EXAS as of 1761868800 were 7935767 with a Short Ratio of 2.89, compared to 1759190400 on 6715031. Therefore, it implies a Short% of Shares Outstanding of 7935767 and a Short% of Float of 4.79.
Earnings Estimates
The firm’s stock currently is rated by 9.0 analysts. The consensus estimate for the next quarter is $0.08, with high estimates of $0.24 and low estimates of -$0.11.
Analysts are recommending an EPS of between $0.56 and $0.27 for the fiscal current year, implying an average EPS of $0.43. EPS for the following year is $1.11, with 9.0 analysts recommending between $1.52 and $0.62.
Revenue Estimates
In. The current quarter, 19 analysts expect revenue to total $859.33M. It ranges from a high estimate of $864.8M to a low estimate of $836.71M. As of. The current estimate, Exact Sciences Corp’s year-ago sales were $713.42MFor the next quarter, 19 analysts are estimating revenue of $830.78M. There is a high estimate of $853.3M for the next quarter, whereas the lowest estimate is $774.68M.
A total of 20 analysts have provided revenue estimates for EXAS’s current fiscal year. The highest revenue estimate was $3.23B, while the lowest revenue estimate was $3.17B, resulting in an average revenue estimate of $3.23B. In the same quarter a year ago, actual revenue was $2.76BBased on 21 analysts’ estimates, the company’s revenue will be $3.65B in the next fiscal year. The high estimate is $3.76B and the low estimate is $3.48B.
